



Therapeutic Targets in Chronic Lymphocytic Leukemia

Guest Editors:

Dr. Luca Laurenti

Institute of Hematology,
Università Cattolica del Sacro
Cuore, Rome, Italy

Dr. Dimitar Efremov

International Centre for Genetic
Engineering and Biotechnology,
Trieste, Italy

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editors

Dear Colleagues,

In recent years, major progress has been made in understanding the cellular and molecular mechanisms that drive chronic lymphocytic leukemia. This knowledge has resulted in the development of novel drugs that have revolutionized treatment of this disease. Among these, drugs that target the B cell receptor pathway and the antiapoptotic protein BCL2 have already been successfully exploited in the clinic and have become available for routine clinical use. However, although most patients initially respond to treatment with these drugs, the vast majority achieve only a partial remission, and a substantial proportion of these subsequently suffer a relapse or undergo Richter transformation, for which no effective treatment currently exists. To further improve treatment responses, combinations of drugs that target patient-specific genetic lesions and common microenvironmental signals will most likely be required.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)